The MegaScan line of monitors formerly sold by EMED found a new home after monitor manufacturer Aydin Displays acquired the business from Access Radiology. The deal should help Aydin expand into the healthcare business from its core activities in
The MegaScan line of monitors formerly sold by EMED found a new home after monitor manufacturer Aydin Displays acquired the business from Access Radiology. The deal should help Aydin expand into the healthcare business from its core activities in military and industrial displays. Terms of the deal were not disclosed.
Teleradiology firm EMED provided MegaScan monitors to PACS OEMs, and Access of Lexington, MA, acquired the line with its purchase of EMED in December (SCAN 11/25/98). Access sold the division to Aydin as part of a larger strategy of focusing on electronic medical imaging technology and systems, according to Scott Sheldon, Access CEO.
Although Aydin Displays has primarily developed CRT monitor technology for military and industrial applications, the Horsham, PA-based company has begun developing active matrix liquid crystal display (AMLCD) flat-panel technology for medical uses. The MegaScan deal offers Aydin a line of high-resolution medical imaging CRT monitors and gives MegaScan financial stability, according to Aydin.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.